

Donna Pauler Ankerst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9206268/publications.pdf>

Version: 2024-02-01

110
papers

10,155
citations

46918

47
h-index

33814

99
g-index

116
all docs

116
docs citations

116
times ranked

11735
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Transplantation After Rescue Allocation—the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis. <i>Transplantation</i> , 2022, 106, 1215-1226.	0.5	7
2	Novel Risk Classification Based on Pyroptosis-Related Genes Defines Immune Microenvironment and Pharmaceutical Landscape for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 447.	1.7	3
3	The Influence of Weather on Fatal Accidents in Austrian Mountains. <i>Weather, Climate, and Society</i> , 2022, 14, 303-310.	0.5	2
4	Angpt2/Tie2 autostimulatory loop controls tumorigenesis. <i>EMBO Molecular Medicine</i> , 2022, 14, e14364.	3.3	7
5	Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials. <i>BMC Urology</i> , 2022, 22, 45.	0.6	3
6	Association between received treatment elements and satisfaction with care for patients with knee osteoarthritis seen in general practice in Denmark. <i>Scandinavian Journal of Primary Health Care</i> , 2021, 39, 257-264.	0.6	2
7	Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. <i>European Urology Focus</i> , 2021, 7, 546-553.	1.6	16
8	Bayesian information criterion approximations to Bayes factors for univariate and multivariate logistic regression models. <i>International Journal of Biostatistics</i> , 2021, 17, 241-266.	0.4	11
9	Validity of machine learning in biology and medicine increased through collaborations across fields of expertise. <i>Nature Machine Intelligence</i> , 2020, 2, 18-24.	8.3	43
10	Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools. <i>BMC Medical Research Methodology</i> , 2019, 19, 191.	1.4	7
11	A strategy for high-dimensional multivariable analysis classifies childhood asthma phenotypes from genetic, immunological, and environmental factors. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1364-1373.	2.7	24
12	Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration. <i>PLoS ONE</i> , 2019, 14, e0208717.	1.1	8
13	Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. <i>European Urology Focus</i> , 2019, 5, 54-61.	1.6	18
14	A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. <i>European Radiology Experimental</i> , 2019, 3, 41.	1.7	55
15	The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial. <i>PLoS ONE</i> , 2018, 13, e0204823.	1.1	6
16	A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. <i>European Urology</i> , 2018, 74, 197-203.	0.9	93
17	Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. <i>European Urology</i> , 2018, 74, 575-582.	0.9	117
18	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018, 168, 1.	2.0	33

#	ARTICLE	IF	CITATIONS
19	A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors. <i>Cancer</i> , 2017, 123, 2413-2421.	2.0	15
20	Response to Comment on Adam et al. Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues. <i>Diabetes</i> 2016;65:3776-3785. <i>Diabetes</i> , 2017, 66, e3-e4.	0.3	1
21	Statistical Methodology and Engineering for Next Generation Clinical Risk Calculators. , 2017, , 275-295.		0
22	Predicting natural forest regeneration: a statistical model based on inventory data. <i>European Journal of Forest Research</i> , 2017, 136, 923-938.	1.1	20
23	Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods. <i>Cancer</i> , 2017, 123, 114-121.	2.0	54
24	Interactions between temperature and drought in global and regional crop yield variability during 1961-2014. <i>PLoS ONE</i> , 2017, 12, e0178339.	1.1	174
25	Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. <i>Prostate</i> , 2016, 76, 1120-1129.	1.2	60
26	Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 355-360.	0.2	29
27	Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues. <i>Diabetes</i> , 2016, 65, 3776-3785.	0.3	49
28	Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome. <i>Medicine (United States)</i> , 2016, 95, e4322.	0.4	18
29	Asymmetric trends in seasonal temperature variability in instrumental records from ten stations in Switzerland, Germany and the UK from 1864 to 2012. <i>International Journal of Climatology</i> , 2016, 36, 13-27.	1.5	34
30	Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. <i>European Urology</i> , 2016, 69, 407-410.	0.9	51
31	MP75-06 ACUTE URINARY STONE INCIDENCE AS A FUNCTION OF TEMPERATURE AND LAG LENGTH IN A SUBTROPICAL CLIMATE. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
32	MP77-09 LONG-TERM RISK OF PROSTATE CANCER IS DIRECTLY RELATED TO BASELINE PSA:. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
33	Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials. <i>Acta Oncologica</i> , 2015, 54, 187-193.	0.8	16
34	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <i>European Urology</i> , 2015, 68, 1083-1088.	0.9	48
35	Association of tree and plot characteristics with microhabitat formation in European beech and Douglas-fir forests. <i>European Journal of Forest Research</i> , 2015, 134, 335-347.	1.1	34
36	Prevalence of Isolated Pre-Malignant Lesions on Prostate Biopsy in a Racially Diverse Community Screened Cohort. <i>Open Journal of Urology</i> , 2015, 05, 213-219.	0.0	1

#	ARTICLE	IF	CITATIONS
37	Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences Into Decision Making. JAMA - Journal of the American Medical Association, 2014, 312, 995.	3.8	34
38	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. World Journal of Urology, 2014, 32, 185-191.	1.2	28
39	Chilling outweighs photoperiod in preventing precocious spring development. Global Change Biology, 2014, 20, 170-182.	4.2	304
40	Assessment of Wildfire Hazards with a Semiparametric Spatial Approach. Environmental Modeling and Assessment, 2014, 19, 533-546.	1.2	2
41	MP69-12 ADDED VALUE OF GENETIC RISK SCORE TO THE PROSTATE CANCER PREVENTION TRIAL (PCPT) RISK CALCULATOR: FINDINGS FROM THE PCPT STUDY. Journal of Urology, 2014, 191, .	0.2	0
42	Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low- vs High-grade Prostate Cancer. Urology, 2014, 83, 1362-1368.	0.5	193
43	Predicting Tree Mortality for European Beech in Southern Germany Using Spatially Explicit Competition Indices. Forest Science, 2014, 60, 613-622.	0.5	12
44	Translational Risk Models. , 2014, , 441-458.		1
45	Prostate cancer incidence and survival in immigrants to Sweden. World Journal of Urology, 2013, 31, 1483-1488.	1.2	9
46	Nutrient status: a missing factor in phenological and pollen research?. Journal of Experimental Botany, 2013, 64, 2081-2092.	2.4	46
47	Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials. Clinical Cancer Research, 2013, 19, 225-235.	3.2	64
48	Real-time Individual Predictions of Prostate Cancer Recurrence Using Joint Models. Biometrics, 2013, 69, 206-213.	0.8	81
49	Risk Calculators. , 2012, , 529-554.		0
50	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology, 2012, 30, 181-187.	1.2	66
51	1218 INCORPORATION OF BODY MASS INDEX AND PROSTATE SIZE INTO A NOMOGRAM FOR SELECTING PATIENTS FOR INITIAL PROSTATE BIOPSY: VALIDATION IN THE PROSTATE CANCER PREVENTION TRIAL. Journal of Urology, 2012, 187, .	0.2	0
52	First flowering of wind-pollinated species with the greatest phenological advances in Europe. Ecography, 2012, 35, 1017-1023.	2.1	32
53	Selective detection of histologically aggressive prostate cancer. Cancer, 2012, 118, 2651-2658.	2.0	20
54	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World Journal of Urology, 2012, 30, 149-155.	1.2	101

#	ARTICLE	IF	CITATIONS
55	Updating risk prediction tools: A case study in prostate cancer. <i>Biometrical Journal</i> , 2012, 54, 127-142.	0.6	26
56	999 SELECTIVE DETECTION OF HISTOLOGICALLY AGGRESSIVE PROSTATE CANCER: VALIDATION BY PCPT COHORT DATA OF AN EDNR PREDICTIVE MODEL TO REDUCE UNNECESSARY PROSTATE BIOPSIES. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
57	Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 317-324.	1.0	6
58	High levels of nucleotide diversity and fast decline of linkage disequilibrium in rye (<i>Secale cereale</i> L.) genes involved in frost response. <i>BMC Plant Biology</i> , 2011, 11, 6.	1.6	55
59	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010, 16, 4374-4381.	3.2	86
60	Afamin and Apolipoprotein A-IV: Novel Protein Markers for Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1127-1133.	1.1	93
61	Screening for Prostate Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 264-273.	157.7	90
62	Clinical score for nonbacterial osteitis in children and adults. <i>Arthritis and Rheumatism</i> , 2009, 60, 1152-1159.	6.7	132
63	Yearly Prostate Specific Antigen and Digital Rectal Examination Fluctuations in a Screened Population. <i>Journal of Urology</i> , 2009, 181, 2071-2076.	0.2	19
64	Sequestosome 1 (SQSTM1) Mutations in Paget's Disease of Bone from the United States. <i>Calcified Tissue International</i> , 2008, 82, 271-277.	1.5	31
65	Total Prostate Specific Antigen Stability Confirmed After Long-Term Storage of Serum at 80C. <i>Journal of Urology</i> , 2008, 180, 534-538.	0.2	6
66	Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3. <i>Journal of Urology</i> , 2008, 180, 1303-1308.	0.2	113
67	Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. <i>Journal of the American Statistical Association</i> , 2008, 103, 1392-1404.	1.8	27
68	Protein Kinase C Inhibition in the Treatment of Mania. <i>Archives of General Psychiatry</i> , 2008, 65, 255.	13.8	197
69	Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer. <i>Tumor Biology</i> , 2008, 29, 272-277.	0.8	33
70	Validation of Biomarker-Based Risk Prediction Models. <i>Clinical Cancer Research</i> , 2008, 14, 5977-5983.	3.2	163
71	The Role of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer: Systematic Review of Randomized Controlled Trials and Meta-Analysis. <i>Oncology</i> , 2007, 72, 314-321.	0.9	75
72	Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2600-2608.	3.0	650

#	ARTICLE	IF	CITATIONS
73	Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1510-1515.	3.0	52
74	Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1966-1972.	1.1	25
75	Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 3076-3081.	0.8	85
76	Longitudinal Analysis of Sexual Function Reported by Men in the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1025-1035.	3.0	80
77	Prostate Cancer Risk with Positive Family History, Normal Prostate Examination Findings, and PSA Less Than 4.0 ng/mL. <i>Urology</i> , 2007, 70, 748-752.	0.5	15
78	Biomarkers for Prostate Cancer Detection. <i>Journal of Urology</i> , 2007, 178, 2252-2259.	0.2	75
79	Understanding Mixed Messages About Prostate Specific Antigen: Biases in the Evaluation of Cancer Biomarkers. <i>Journal of Urology</i> , 2007, 177, 426-427.	0.2	5
80	Status of quality of life in breast cancer research before, during and beyond treatment. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2006, 6, 207-214.	0.7	1
81	Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2006, 98, 529-534.	3.0	851
82	Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 969-995.	2.5	231
83	External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. <i>Urology</i> , 2006, 68, 1152-1155.	0.5	104
84	Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: A meta-analysis. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 1-25.	0.9	209
85	Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16. <i>Journal of the National Cancer Institute</i> , 2006, 98, 516-521.	3.0	273
86	Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone. <i>Journal of Clinical Oncology</i> , 2006, 24, 2828-2835.	0.8	80
87	Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1331-1335.	1.1	121
88	Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1128-1133.	3.0	292
89	Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. <i>Archivio Italiano Di Urologia Andrologia</i> , 2006, 78, 125-9.	0.4	25
90	Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool. <i>Archivio Italiano Di Urologia Andrologia</i> , 2006, 78, 143-6.	0.4	3

#	ARTICLE	IF	CITATIONS
91	New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2006, 78, 154-6.	0.4	3
92	An Educational Program to Increase Cervical and Breast Cancer Screening in Hispanic Women. <i>Cancer Nursing</i> , 2005, 28, 47-53.	0.7	79
93	An Estimator for Treatment Comparisons among Survivors in Randomized Trials. <i>Biometrics</i> , 2005, 61, 305-310.	0.8	90
94	Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 66.	3.8	586
95	Clinical Monitoring Based on Joint Models for Longitudinal Biomarkers and Event Times. , 2005, , 383-394.		1
96	Rates of study completion with single versus split daily dosing of antidepressants: a meta-analysis. <i>Journal of Affective Disorders</i> , 2004, 78, 157-162.	2.0	18
97	Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≥ 4.0 ng per Milliliter. <i>New England Journal of Medicine</i> , 2004, 350, 2239-2246.	13.9	2,174
98	Optimism, Perceived Risk of Breast Cancer, and Cancer Worry Among a Community-Based Sample of Women.. <i>Health Psychology</i> , 2004, 23, 339-344.	1.3	48
99	Effect of Cryopreservation on Assays of Antigen-Specific T Cells: Comparison of Tetramer, Cytokine Flow Cytometry, and ELISPOT. <i>Journal of Immunotherapy</i> , 2004, 27, S42.	1.2	0
100	Pattern mixture models for longitudinal quality of life studies in advanced stage disease. <i>Statistics in Medicine</i> , 2003, 22, 795-809.	0.8	82
101	Health Status and Quality of Life in Patients With Early-Stage Hodgkin's Disease Treated on Southwest Oncology Group Study 9133. <i>Journal of Clinical Oncology</i> , 2003, 21, 3512-3519.	0.8	90
102	Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. <i>Statistics in Medicine</i> , 2002, 21, 3897-3911.	0.8	54
103	Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Change-point and Mixture Models of Longitudinal Markers. <i>Journal of the American Statistical Association</i> , 2001, 96, 429-439.	1.8	125
104	Differential Regulation of Inhibin A and Inhibin B by Luteinizing Hormone, Follicle-Stimulating Hormone, and Stage of Follicle Development. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2531-2537.	1.8	48
105	A Mixture Model for Longitudinal Data with Application to Assessment of Noncompliance. <i>Biometrics</i> , 2000, 56, 464-472.	0.8	43
106	Primary Medical Therapy of Micro- and Macroprolactinomas in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3053-3057.	1.8	95
107	Bayes Factors and Approximations for Variance Component Models. <i>Journal of the American Statistical Association</i> , 1999, 94, 1242-1253.	1.8	71
108	The Schwarz criterion and related methods for normal linear models. <i>Biometrika</i> , 1998, 85, 13-27.	1.3	112

#	ARTICLE	IF	CITATIONS
109	Differential Age-Related Loss of Pigmented Locus Coeruleus Neurons in Suicides, Alcoholics, and Alcoholic Suicides. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1141-1148.	1.4	18
110	Mixture analysis of pursuit eye-tracking dysfunction in schizophrenia. <i>Biological Psychiatry</i> , 1993, 34, 331-340.	0.7	33